Age-specific and sex-specific risks for HCC in African-born persons with chronic hepatitis B without cirrhosisShow others and affiliations
2023 (English)In: Hepatology communications, E-ISSN 2471-254X, Vol. 7, no 12, article id e0334Article in journal (Refereed) Published
Abstract [en]
BACKGROUND: The international recommendations of HCC surveillance for African-born persons with chronic hepatitis B (CHB) without cirrhosis are divergent, probably due to scarce data on incidence rate (IR) for HCC.
METHODS: We assembled a cohort with prospectively collected data of Swedish residents of African origin with diagnosed CHB without cirrhosis at baseline from 1990 to 2015. Data from nationwide registers were used to calculate the sex-specific IR and IR ratio (incidence rate ratios) in relation to age, comorbidities, and birth region, using a generalized linear model with a log-link function and Poisson distribution.
RESULTS: Among 3865 African-born persons with CHB without cirrhosis at baseline, 31 (0.8%; 77.4% men) developed HCC during a median of 11.1 years of follow-up, with poor survival after HCC diagnosis. The mean age at HCC diagnosis was 46.8 (SD±14.7; range 23-79) in men. HCC IR exceeded the recommended surveillance threshold of 0.2%/year at ages 54 and 59 years in men and women, respectively, and at ages 20-40 years if HCV or HDV co-infection was present. African-born men with CHB had an incidence rate ratios of 10.6 (95% CI 4.4-31.5) for HCC compared to matched African-born peers without CHB, and an incidence rate ratios of 35.3 (95% CI 16.0-88.7) compared to a matched general population.
CONCLUSIONS: African-born men with CHB without cirrhosis reached an IR of 0.2%/year between 50 and 60 years, and at younger ages if HCV or HDV co-infection was present. Our findings need further confirmation, and new cost-effectiveness analyses specific for young populations are needed, to provide personalized and cost-effective HCC surveillance.
Place, publisher, year, edition, pages
Wiley Periodicals Inc. on behalf of the American Association for the Study of Liver Diseases , 2023. Vol. 7, no 12, article id e0334
National Category
Infectious Medicine
Research subject
Infectious Diseases
Identifiers
URN: urn:nbn:se:oru:diva-110909DOI: 10.1097/HC9.0000000000000334ISI: 001112327800005PubMedID: 38051538OAI: oai:DiVA.org:oru-110909DiVA, id: diva2:1829754
Note
Habiba Kamal received research grants from Gilead. Per Stal is on the speakers' bureau for Roche, Albireo, and Eisai. Heiner Wedemeyer consults for AstraZeneca, Eisai, and MSD. Ann-Sofi Duberg advises and is on the speakers' bureau for Gilead. Soo Aleman is on the speakers' bureau for Gilead.
2024-01-192024-01-192024-01-22Bibliographically approved